Jazz Pharmaceuticals’ zanidatamab shows promising results in HER2-positive biliary tract cancer
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) has released pivotal new data from its Phase 2b HERIZON-BTC-01 clinical trial assessing zanidatamab in previously treated HER2-positive biliary tract ... Read More
Jazz Pharmaceuticals to acquire Redx Pharma’s KRAS inhibitor program to expand oncology pipeline
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) and Redx Pharma plc (AIM: REDX) have entered into a definitive agreement, marking a significant milestone in the development of ... Read More
Axsome Therapeutics to acquire Sunosi from Jazz Pharmaceuticals
Axsome Therapeutics has agreed to acquire Sunosi (solriamfetol), an approved dual-acting dopamine and norepinephrine reuptake inhibitor (DNRI), from Jazz Pharmaceuticals. Sunosi is indicated to improve ... Read More
Jazz Pharmaceuticals gets Rylaze FDA approval for ALL and LBL
Rylaze FDA approval : Jazz Pharmaceuticals has secured approval for its leukemia drug Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn or JZP458) from the US Food and ... Read More
Jazz Pharmaceuticals to acquire GW Pharmaceuticals in $7.2bn deal
In a significant move within the pharmaceutical industry, Irish biopharma company Jazz Pharmaceuticals has announced an agreement to acquire British-based GW Pharmaceuticals in a monumental ... Read More